NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...

NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

NewAmsterdam Pharma's obicetrapib demonstrates strong phase 3 results. Discover why NAMS stock could rise as further studies ...

Santhera Pharmaceuticals gains approval in China for Agamree, the first Duchenne muscular dystrophy therapy available for ...

Scotiabank analyst George Farmer raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $47 from $35 and keeps an Outperform rating on ...

Scotiabank analyst George Farmer maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today and set a price target ...

Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...

On Dec. 7, Adaptive Biotechnologies presented new data at ASH 2024 showcasing clonoSEQ MRD testing advances and its role in ...

New York Mortgage Trust, Inc. is a Maryland corporation that has elected to be taxed as a real estate investment trust ("REIT”) for federal income tax purposes. NYMT is an internally managed REIT in ...

NewAmsterdam Pharma’s cardio drug succeeded in a third readout this year, showing that obicetrapib could lower a type of ...

NewAmsterdam Pharma (Nasdaq: NAMS) took a commanding leap in the stock market, thanks to the announcement of positive topline data from its Phase 3 BROADWAY clinical trial. This trial evaluated ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...